linerixibat

Small moleculeexperimental

Clinical trial activity

15 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
6
Phase 3
2
Phase 4
0

Earliest trial started Jun 15, 2011 (NCT01416324)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(=O)O)CC(=O)O)c(OC)cc2[C@@H](c2ccccc2)N1
Mol. weight
546.69 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3-((((3r,5r)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino)pentanedioic acid
  • gsk2230672
  • gsk2330672
  • gsk2330672
  • gsk2330672

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05435170Phase 1Aug 11, 2022GlaxoSmithKline
NCT05393076Phase 1Jun 17, 2022GlaxoSmithKline
NCT05133830Phase 1Nov 23, 2021GlaxoSmithKline
NCT04950127Phase 3Aug 27, 2021GlaxoSmithKline
NCT04167358Phase 3Jan 10, 2020GlaxoSmithKline
NCT04053023Phase 1Aug 21, 2019GlaxoSmithKline
NCT03992014Phase 1Jul 1, 2019GlaxoSmithKline
NCT02966834Phase 2Jan 10, 2017GlaxoSmithKline
NCT02801981Phase 1Jun 1, 2016GlaxoSmithKline
NCT02202161Phase 2Aug 1, 2014GlaxoSmithKline
NCT01899703Phase 2Mar 1, 2014GlaxoSmithKline
NCT01929863Phase 2Aug 1, 2013GlaxoSmithKline
NCT01607385Phase 1May 18, 2012GlaxoSmithKline
NCT01416324Phase 1Jun 15, 2011GlaxoSmithKline
NCT05448170N/AGlaxoSmithKline
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit151542011
1 organizations
Page 1 / 1